Annual Conference
Live Virtual Program was held Thursday, March 18, 2021 – Saturday, March 20, 2021. View a press release about the event.
Continuing Education
More than 35 recorded educational sessions from the NCCN 2021 Virtual Annual Conference are now available!
View topics below or visit education.nccn.org/ac2021 for
more information.
Keynote Sessions
- Keynote Session: Effects of the Pandemic on Cancer Care/Future Directions of Cancer Care
- Keynote Session: Reducing Racial Disparities in Oncology - Recommendations for Implementing Guideline-Adherent Cancer Care
- Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers
Best Practices in Oncology
- Best Practices for Incorporating Patient-Reported Outcomes into Oncology Care
- Effects of White and Brown Bagging on Oncology Practice
- The Role of Advanced Practice Providers in Oncology Care
- Keynote Session: Effects of the Pandemic on Cancer Care/Future Directions of Cancer Care
Breast Cancer
- Challenging Case Review: Breast Cancer
- NCCN Guidelines® Update: HER2-Positive Breast Cancer
- NCCN Guidelines® Update: Triple Negative Breast Cancer
Cutaneous Melanoma
- Cutaneous Melanoma: Management of Melanoma Brain Metastases
- Molecular Testing for Cutaneous Melanoma
Gastrointestinal Cancers
- Challenging Case Review: Colorectal Cancer
- NCCN Guidelines® Updates: Gastric and Esophageal Cancers
- New Systemic Treatment Options for Hepatobiliary Cancers
- Treatment of Locally Advanced Colorectal Cancer
Genitourinary Cancers
- Management of Metastatic Castration-Resistant Prostate Cancer
- New Settings for Immune Checkpoint Inhibitors in Urothelial Bladder Cancer
- Screening, Diagnosis, and Management of Hereditary Renal Cell Carcinoma
- Surgical Management of Testicular Germ Cell Tumors
Gynecological Malignancies
- NCCN Guidelines® Updates: Uterine Cancers
- Use of PARP Inhibitors for Ovarian Cancer
- Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers
Head and Neck Cancers
- Evolving Treatment Options for Salivary Gland Tumors
- Supportive Care in Head and Neck Cancers: Multidisciplinary Management
- Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers
Hematologic Malignancies
- NCCN Guidelines® Update: Multiple Myeloma
- Treatment Updates in Acute Myeloid Leukemia
- Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease
- Updates on CAR T-cell Therapy for Relapsed/Refractory B-Cell Lymphomas
Non-Small Cell Lung Cancer
- Challenging Case Review: Non-Small Cell Lung Cancer
- New Targeted Therapies and Immunotherapies for Metastatic Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: Biomarker Testing Recommendations
Supportive Care/Survivorship
- Advances in Oncofertility: Fertility Preservation Options for Adolescents and Young Adults with Cancer
- Helping Cancer Survivors Return to Work
- Importance of Primary Care Physician Involvement in Cancer Care
- Supportive Care in Head and Neck Cancers: Multidisciplinary Management
Other Topics
This activity is supported by educational grants from:
- Abbott's molecular business
- Adaptive Biotechnologies
- AstraZeneca
- BeiGene, Ltd.
- Blueprint Medicines
- Daiichi Sankyo
- Deciphera Pharmaceuticals
- Eisai
- Exact Sciences
- Genentech, a member of the Roche Group
- Gilead Sciences
- GlaxoSmithKline
- GRAIL, Inc.
- Ipsen Biopharmaceuticals, Inc.
- Jazz Pharmaceuticals, Inc.
- Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
- Lilly
- Olympus Corporation of the Americas
- Novartis
- Pfizer
- Puma Biotechnology
- Seagen Inc. formerly Seattle Genetics
- Taiho Oncology, Inc.
- TeSera Therapeutics
This activity is supported by independent medical education grants from:
- Bristol Myers Squibb
- Illumina, Inc.
- Regeneron Pharmaceuticals, Inc and Sanofi Genzyme
This activity is supported by independent educational grants from:
- AbbVie
- Astellas
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Incyte
- Merck & Co., Inc.
This activity is supported by educational funding provided by Amgen.
This educational activity is supported by a medical education grant from Exelixis, Inc. & Karyopharm® Therapeutics.
This project has been made possible in part by a grant from Varian Medical Systems/Global Medical Education Grant Program.
Additional activities
- View recorded presentations from the NCCN 2021 Virtual Nursing Program: Advancing Oncology Nursing™
- View recorded presentations from the NCCN 2021 Virtual Oncology Fellows Program: New Horizons in Quality Cancer Care
General Poster Session
View abstracts from the NCCN 2021 Virtual Annual Conference in JNCCN-Journal of the National Comprehensive Cancer Network.
More than 90 posters were accepted to participate in the NCCN Virtual Poster Exhibition Hall throughout the following categories.
- Clinical Oncology (all phases)
- Epidemiology/Risks/Prevention
- Best Practices in Implementation and Use of Clinical Practice Guidelines
- Quality Improvement
- Outcomes and Health Services Research
- Bioinformatics/Information Technology Sciences
Virtual Exhibition Hall
The virtual event included the NCCN Virtual Exhibition Hall, the Reimbursement Resource Room, and Patient Advocacy Pavilion.
Platinum Level Sponsors
Gold Level Sponsors
Janssen Oncology
Pharmacyclics LLC., an AbbVie Company
Silver Level Sponsor
Bronze Level Sponsors
AstraZeneca
BeiGene
Jazz Pharmaceuticals
Sanofi Genzyme
Servier
NCCN Patient Advocacy Pavilion Sponsors
Ruby
Pharmacyclics
Emerald
AstraZeneca
BeiGene, Ltd.
Coherus BioSciences
Eisai Inc.
Gilead-Kite Oncology
Incyte
Janssen
Karyopharm Therapeutics Inc.
Oncopeptides
Topaz
AbbVie
AmerisourceBergen
GSK
Natera
Novartis
Jade
Virtual Reimbursement Resource Room
Corporate Council
Global Corporate Council
Save the Date!
NCCN 2022 Annual Conference
Thursday, March 31, 2022 – Saturday, April 2, 2022